Gastric peroral endoscopic pyloromyotomy for delayed gastric conduit emptying: outcomes and predictors of treatment response - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Gastric Peroral Endoscopic Pyloromyotomy for Delayed Gastric Conduit Emptying: Treatment Outcomes and Predictors of Response

  • By

  • L. S. Boer

  • C. A. C. ‘t Hoen

  • I. N. Beaufort

  • B. A. J. Bastiaansen

  • P. Fockens

  • L. Noteboom

  • C. M. G. Saleh

  • S. S. Gisbertz

  • B. L. A. M. Weusten

  • October 15, 2026

Share

  • 1

    Delayed gastric conduit emptying affects approximately 15% to 50% of patients after esophagectomy and can impair quality of life.

  • 2

    The prospective study evaluated GPOEM efficacy, safety, and potential predictors of response in patients with refractory DGCE after esophagectomy.

  • 3

    Adults were eligible if symptoms began more than 3 months after esophagectomy, resisted dietary and prokinetic treatment, and had at least 1 objective finding of DGCE.

  • 4

    Patients underwent GPOEM at 2 academic centers in the Netherlands between March 2021 and December 2024.

  • 5

    Assessments included EndoFLIP and gastric emptying scintigraphy before treatment and at 3 months, with follow-up endoscopy and symptom and quality-of-life measures after treatment.

Original Source(s)

Gastric peroral endoscopic pyloromyotomy for delayed gastric conduit emptying: outcomes and predictors of treatment response

  • by L. S. Boer, C. A. C. ‘t Hoen, I. N. Beaufort, B. A. J. Bastiaansen, P. Fockens, L. Noteboom, C. M. G. Saleh, S. S. Gisbertz, B. L. A. M. Weusten

  • October 15, 2026

Related Content

5.0 T versus 1.5 T and 3.0 T upper abdominal MRI: a prospective two‑cohort study of image quality and diagnostic confidence

Correction: Evaluation of endoscopic submucosal dissection as a treatment option for duodenal tumors ≥ 20 mm: a systematic review and meta-analysis by lesion size

HBsAg decline and clearance with peg-IFN therapy added to nucleos(t)ide analogues: an individual participant data meta-analysis of prospective trials (PROSPER)